Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 12Triple Negative Breast Neoplasms 5Ovarian Neoplasms 4Advanced Solid Tumors 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2mCRPC 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Fanconi Anemia, Complementation Group D1 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Adenocarcinoma 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × ATM Gene Mutation × talazoparib × Clear all
NCT03377556 2021-06-23

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2 Completed
51 enrolled 18 charts

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡